Class Action Reports

PRVB Class Action: Learn About the Provention Bio Lawsuit

Levi & Korsinsky, LLP

May 25, 2021

Levi & Korsinsky, LLP announces that a PRVB class action lawsuit has been filed on behalf of investors who purchased Provention Bio, Inc. (PRVB) securities between November 2, 2020 – April 8, 2021. For more on the PRVB Lawsuit please contact us today.

 

According to the Provention Bio lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application (“BLA”) was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA’s approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

 

TO LEARN MORE ABOUT THE PRVB CLASS ACTION LAWSUIT, CLICK HERE

 

If you suffered a loss in Provention Bio you have until July 20, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

 

 

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com